Skip to content
Clinical Trials – home

Centre Hospitalier De Versailles

Verified siteinfo

France 177 Rue De Versailles, Le Chesnay, 78150 Le Chesnay-Rocquencourt, France

  • 59 trials recruiting
  • Acute myeloid leukaemia · Plasma cell myeloma · Acute lymphocytic leukaemia
  • Adults and children

About Specializations

Centre Hospitalier De Versailles in Le Chesnay-Rocquencourt, France specialises in clinical trials of conditions such as Acute myeloid leukaemia, Plasma cell myeloma, Acute lymphocytic leukaemia, Chronic myeloid leukaemia, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Research

The medical center is at the forefront of cardiovascular research, focusing on innovative treatments for conditions such as acute myocardial infarction and cardiac failure. The center's research aims to improve patient outcomes through advanced therapeutic strategies.

  • Acute Myocardial Infarction
  • Cardiac Remodeling
  • Heart Failure Management

By integrating cutting-edge therapies like evolocumab and dapagliflozin, the center is enhancing the standard of care for cardiovascular patients.

Oncology and Hematology

Specializing in oncology and hematology, the center conducts pivotal trials in multiple myeloma, chronic myeloid leukemia, and acute lymphoblastic leukemia. These studies are crucial for developing new treatment protocols and improving survival rates.

  • Multiple Myeloma
  • Chronic Myeloid Leukemia
  • Acute Lymphoblastic Leukemia

Through the exploration of novel drug combinations and targeted therapies, the center is advancing the field of cancer treatment.

Neurology and Stroke

The center is pioneering research in neurology, with a focus on stroke management and recovery. By investigating new thrombolytic agents and treatment windows, the center aims to enhance neurological outcomes for stroke patients.

  • Acute Ischaemic Stroke
  • Neurological Recovery
  • Thrombolytic Therapy

Innovative approaches in stroke care are being developed to improve patient quality of life and reduce long-term disability.

Respiratory and Infectious Diseases

Focusing on respiratory and infectious diseases, the center is conducting research on conditions like severe influenza and chronic obstructive pulmonary disease (COPD). These studies aim to optimize treatment regimens and improve patient outcomes.

  • Severe Influenza
  • Chronic Obstructive Pulmonary Disease
  • Infectious Disease Management

By exploring new therapeutic strategies, the center is enhancing the management of complex respiratory conditions.

Immunology and Autoimmune Disorders

The center is advancing the field of immunology through research on autoimmune disorders such as giant cell arteritis and familial Mediterranean fever. These studies focus on novel treatments to improve patient care and disease management.

  • Giant Cell Arteritis
  • Familial Mediterranean Fever
  • Autoimmune Disease Management

Innovative therapies are being developed to target the underlying mechanisms of autoimmune diseases, offering hope for improved patient outcomes.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
177 Rue De Versailles, Le Chesnay78150 Le Chesnay-RocquencourtFrance
Recruiting now
59 trials
Conditions studied
91
Partner status
Verified site

More sites in Le Chesnay-RocquencourtFrance

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

124 clinical trials

A Phase III Study of Survodutide in Adults with Compensated NASH Cirrhosis to Assess Liver Outcomes and Safety

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim International GmbH

A Phase III trial of BI 456906 weekly injections in adults with NASH and stage 2‑3 liver fibrosis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim International GmbH

Asthma

Recruiting

A Study of Brenipatide Compared to Placebo for Adults with Uncontrolled Moderate to Severe Asthma

Investigational
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:LY3537031
  • Sponsor:Eli Lilly & Co.

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Hepatic fibrosis+2

Recruiting

Study on Efruxifermin for Patients with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH) and Fibrosis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Efruxifermin
  • Sponsor:Akero Therapeutics Inc.

Hepatic cirrhosis+2

Recruiting

Study on Efruxifermin for Patients with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) or Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Efruxifermin
  • Sponsor:Akero Therapeutics Inc.

Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Asthma

Recruiting

Efficacy and safety of GB-0895 as adjunctive therapy in adults and adolescents with severe uncontrolled asthma (randomized, placebo‑controlled)

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Generate Biomedicines Inc.

Cardiac failure+1

Recruiting

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Novo Nordisk A/S

Study of blinatumomab and a drug combination for older adults with newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Asparaginase
  • Sponsor:Amgen Inc.

Study of ziftomenib with drug combinations for adults with newly diagnosed acute myeloid leukemia with NPM1 or KMT2A genetic changes

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Kura Oncology Inc.

A study testing prednisone combined with antibiotics compared to antibiotics alone in adults with septic arthritis to improve joint health

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Assistance Publique Hopitaux De Paris
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.